Early predictors of rapidly evolving multiple sclerosis: A case report
Objective The aim of this case report is to highlight some important features of rapidly evolving Multiple Sclerosis. In a small proportion of patients, Multiple Sclerosis (MS) can present as a fulminant disease characterised by severe and frequent relapses. This form of rapidly evolving MS is assoc...
Saved in:
| Published in: | Journal of neuroimmunology Vol. 307; pp. 42 - 46 |
|---|---|
| Main Authors: | , |
| Format: | Journal Article |
| Language: | English |
| Published: |
Netherlands
Elsevier B.V
15.06.2017
|
| Subjects: | |
| ISSN: | 0165-5728, 1872-8421, 1872-8421 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Objective
The aim of this case report is to highlight some important features of rapidly evolving Multiple Sclerosis.
In a small proportion of patients, Multiple Sclerosis (MS) can present as a fulminant disease characterised by severe and frequent relapses. This form of rapidly evolving MS is associated with significant morbidity and mortality. It is therefore important to identify these patients as early as possible, so that they can be managed effectively. However, due to the rarity of fulminant forms of MS, there is limited data on the natural history and management of this condition.
We present a young man with rapidly evolving Multiple Sclerosis (MS) who had 2 disabling relapses within 14weeks. He had an unusually high CSF white cell count at presentation (86per mm3; 100% lymphocytes, 97% T cells, 3% B cells), with positive oligoclonal bands. Brain MRI showed large, cavitating lesions, with no enhancement. He required a prolonged course of intravenous methyl-prednisolone and plasma exchange.
This case suggests that male gender, young age at onset, time to second relapse, relapse severity, high CSF white cell count at presentation, large and cavitating lesions on MRI may be early predictors of rapidly evolving MS. It also highlights the therapeutic value of plasma exchange and longer courses of intravenous methylprednisolone in managing severe MS relapses. Enhancement may not always be a reliable indicator of disease activity, particularly in clinical settings where single dose gadolinium is used, due to its low sensitivity in detecting blood brain barrier leakage. |
|---|---|
| AbstractList | Objective
The aim of this case report is to highlight some important features of rapidly evolving Multiple Sclerosis.
In a small proportion of patients, Multiple Sclerosis (MS) can present as a fulminant disease characterised by severe and frequent relapses. This form of rapidly evolving MS is associated with significant morbidity and mortality. It is therefore important to identify these patients as early as possible, so that they can be managed effectively. However, due to the rarity of fulminant forms of MS, there is limited data on the natural history and management of this condition.
We present a young man with rapidly evolving Multiple Sclerosis (MS) who had 2 disabling relapses within 14weeks. He had an unusually high CSF white cell count at presentation (86per mm3; 100% lymphocytes, 97% T cells, 3% B cells), with positive oligoclonal bands. Brain MRI showed large, cavitating lesions, with no enhancement. He required a prolonged course of intravenous methyl-prednisolone and plasma exchange.
This case suggests that male gender, young age at onset, time to second relapse, relapse severity, high CSF white cell count at presentation, large and cavitating lesions on MRI may be early predictors of rapidly evolving MS. It also highlights the therapeutic value of plasma exchange and longer courses of intravenous methylprednisolone in managing severe MS relapses. Enhancement may not always be a reliable indicator of disease activity, particularly in clinical settings where single dose gadolinium is used, due to its low sensitivity in detecting blood brain barrier leakage. Objective The aim of this case report is to highlight some important features of rapidly evolving Multiple Sclerosis.Objective The aim of this case report is to highlight some important features of rapidly evolving Multiple Sclerosis.In a small proportion of patients, Multiple Sclerosis (MS) can present as a fulminant disease characterised by severe and frequent relapses. This form of rapidly evolving MS is associated with significant morbidity and mortality. It is therefore important to identify these patients as early as possible, so that they can be managed effectively. However, due to the rarity of fulminant forms of MS, there is limited data on the natural history and management of this condition.BACKGROUNDIn a small proportion of patients, Multiple Sclerosis (MS) can present as a fulminant disease characterised by severe and frequent relapses. This form of rapidly evolving MS is associated with significant morbidity and mortality. It is therefore important to identify these patients as early as possible, so that they can be managed effectively. However, due to the rarity of fulminant forms of MS, there is limited data on the natural history and management of this condition.We present a young man with rapidly evolving Multiple Sclerosis (MS) who had 2 disabling relapses within 14weeks. He had an unusually high CSF white cell count at presentation (86per mm3; 100% lymphocytes, 97% T cells, 3% B cells), with positive oligoclonal bands. Brain MRI showed large, cavitating lesions, with no enhancement. He required a prolonged course of intravenous methyl-prednisolone and plasma exchange.CASE REPORTWe present a young man with rapidly evolving Multiple Sclerosis (MS) who had 2 disabling relapses within 14weeks. He had an unusually high CSF white cell count at presentation (86per mm3; 100% lymphocytes, 97% T cells, 3% B cells), with positive oligoclonal bands. Brain MRI showed large, cavitating lesions, with no enhancement. He required a prolonged course of intravenous methyl-prednisolone and plasma exchange.This case suggests that male gender, young age at onset, time to second relapse, relapse severity, high CSF white cell count at presentation, large and cavitating lesions on MRI may be early predictors of rapidly evolving MS. It also highlights the therapeutic value of plasma exchange and longer courses of intravenous methylprednisolone in managing severe MS relapses. Enhancement may not always be a reliable indicator of disease activity, particularly in clinical settings where single dose gadolinium is used, due to its low sensitivity in detecting blood brain barrier leakage.CONCLUSIONSThis case suggests that male gender, young age at onset, time to second relapse, relapse severity, high CSF white cell count at presentation, large and cavitating lesions on MRI may be early predictors of rapidly evolving MS. It also highlights the therapeutic value of plasma exchange and longer courses of intravenous methylprednisolone in managing severe MS relapses. Enhancement may not always be a reliable indicator of disease activity, particularly in clinical settings where single dose gadolinium is used, due to its low sensitivity in detecting blood brain barrier leakage. Objective The aim of this case report is to highlight some important features of rapidly evolving Multiple Sclerosis. In a small proportion of patients, Multiple Sclerosis (MS) can present as a fulminant disease characterised by severe and frequent relapses. This form of rapidly evolving MS is associated with significant morbidity and mortality. It is therefore important to identify these patients as early as possible, so that they can be managed effectively. However, due to the rarity of fulminant forms of MS, there is limited data on the natural history and management of this condition. We present a young man with rapidly evolving Multiple Sclerosis (MS) who had 2 disabling relapses within 14weeks. He had an unusually high CSF white cell count at presentation (86per mm ; 100% lymphocytes, 97% T cells, 3% B cells), with positive oligoclonal bands. Brain MRI showed large, cavitating lesions, with no enhancement. He required a prolonged course of intravenous methyl-prednisolone and plasma exchange. This case suggests that male gender, young age at onset, time to second relapse, relapse severity, high CSF white cell count at presentation, large and cavitating lesions on MRI may be early predictors of rapidly evolving MS. It also highlights the therapeutic value of plasma exchange and longer courses of intravenous methylprednisolone in managing severe MS relapses. Enhancement may not always be a reliable indicator of disease activity, particularly in clinical settings where single dose gadolinium is used, due to its low sensitivity in detecting blood brain barrier leakage. Abstract Objective The aim of this case report is to highlight some important features of rapidly evolving Multiple Sclerosis. Background In a small proportion of patients, Multiple Sclerosis (MS) can present as a fulminant disease characterised by severe and frequent relapses. This form of rapidly evolving MS is associated with significant morbidity and mortality. It is therefore important to identify these patients as early as possible, so that they can be managed effectively. However, due to the rarity of fulminant forms of MS, there is limited data on the natural history and management of this condition. Case Report We present a young man with rapidly evolving Multiple Sclerosis (MS) who had 2 disabling relapses within 14 weeks. He had an unusually high CSF white cell count at presentation (86 per mm3 ; 100% lymphocytes, 97% T cells, 3% B cells), with positive oligoclonal bands. Brain MRI showed large, cavitating lesions, with no enhancement. He required a prolonged course of intravenous methyl-prednisolone and plasma exchange. Conclusions This case suggests that male gender, young age at onset, time to second relapse, relapse severity, high CSF white cell count at presentation, large and cavitating lesions on MRI may be early predictors of rapidly evolving MS. It also highlights the therapeutic value of plasma exchange and longer courses of intravenous methylprednisolone in managing severe MS relapses. Enhancement may not always be a reliable indicator of disease activity, particularly in clinical settings where single dose gadolinium is used, due to its low sensitivity in detecting blood brain barrier leakage. |
| Author | James, Michael Fernando, Kryshani T.M. |
| Author_xml | – sequence: 1 givenname: Kryshani T.M. surname: Fernando fullname: Fernando, Kryshani T.M. email: kryshani.fernando@nhs.net organization: Department of Neurology, Watford General Hospital, Hertfordshire, United Kingdom – sequence: 2 givenname: Michael surname: James fullname: James, Michael organization: Department of Neurology, Royal Free Hospital, London, United Kingdom |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28495137$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkk9r3DAQxUVJSTZpvkLwsRe7M5L_llIaQtIUAj0kPQtZHhe5suVK9sJ--2jZpIcckp4eiN97aN7MKTua3ESMXSBkCFh-GrJhotU7M2YcsMpAZFHesQ3WFU_rnOMR20SwSIuK1yfsNIQBAAuRN8fshNd5U6CoNuzmWnm7S2ZPndGL8yFxfeLVbLr4Sltnt2b6nYyrXcxsKQnaknfBhM_JZaJVoMTT7Pzygb3vlQ10_qRn7NfN9cPVbXr38_uPq8u7VOdVvaSoCKhVHEFj10CViw54WYLoeiwUbwRxbIu6ypsO6gZ7aKsWFCjO27LHNhdn7OMhd_bu70phkaMJmqxVE7k1SKybBlEAryJ68YSu7UidnL0Zld_J59kjUB4AHScKnvp_CILclywH-Vyy3JcsQcgo0fjlhVGbRS3GTYtXxr5t_3awUyxqa8jLoA1NOm7Ak15k58zbEV9fRGhrJqOV_UM7CoNb_RTXIFEGLkHe7w9hfwdYChCA8HrA__zgET56xlk |
| CitedBy_id | crossref_primary_10_1002_ccr3_8508 crossref_primary_10_2478_sjecr_2021_0054 |
| Cites_doi | 10.1191/1352458503ms914oa 10.1016/B978-0-444-52001-2.00015-7 10.1212/WNL.58.1.143 10.1212/01.wnl.0000342458.39625.91 10.1002/1531-8249(199912)46:6<878::AID-ANA10>3.0.CO;2-Q 10.1212/01.wnl.0000260064.77700.fd 10.1093/brain/116.1.117 10.1093/brain/112.6.1419 10.1002/ana.410290206 10.1093/brain/120.7.1149 10.1093/brain/awn098 10.1093/brain/awg081 10.1056/NEJMoa044397 10.1093/brain/114.2.1045 10.1002/ana.20703 10.1038/ni1507 10.1093/brain/103.2.281 10.1212/WNL.0b013e31821e559d 10.1056/NEJMoa011341 10.1038/nrneurol.2015.85 10.1212/WNL.46.4.907 |
| ContentType | Journal Article |
| Copyright | 2017 Copyright © 2017. Published by Elsevier B.V. |
| Copyright_xml | – notice: 2017 – notice: Copyright © 2017. Published by Elsevier B.V. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1016/j.jneuroim.2017.03.017 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Anatomy & Physiology |
| EISSN | 1872-8421 |
| EndPage | 46 |
| ExternalDocumentID | 28495137 10_1016_j_jneuroim_2017_03_017 S0165572816303010 1_s2_0_S0165572816303010 |
| Genre | Journal Article Case Reports |
| GroupedDBID | --- --K --M .1- .FO .~1 0R~ 1B1 1P~ 1RT 1~. 1~5 4.4 457 4CK 4G. 5GY 5VS 7-5 71M 8P~ 9JM AAAJQ AABNK AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AARKO AATTM AAXKI AAXLA AAXUO AAYWO ABBQC ABCQJ ABFNM ABFRF ABIVO ABJNI ABMAC ABMZM ABTEW ACDAQ ACGFO ACGFS ACIEU ACIUM ACLOT ACRLP ACVFH ADBBV ADCNI ADEZE AEBSH AEFWE AEIPS AEKER AENEX AEUPX AEVXI AFPUW AFRHN AFTJW AFXIZ AGEKW AGHFR AGUBO AGWIK AGYEJ AIEXJ AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP AXJTR BKOJK BLXMC BNPGV CJTIS CNWQP CS3 DU5 EBS EFJIC EFKBS EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FIRID FNPLU FYGXN G-Q GBLVA HMO HMQ IHE J1W KOM L7B LUGTX LX8 M29 M2V M41 MO0 MOBAO N9A O-L O9- OAUVE OP~ OZT P-8 P-9 P2P PC. Q38 ROL RPZ SCC SDF SDG SDP SEL SES SPCBC SSH SSI SSN SSZ T5K UNMZH Z5R ~G- ~HD .GJ 29L 53G AACTN AAQXK ABWVN ABXDB ACRPL ADMUD ADNMO AFCTW AFJKZ AFKWA AHHHB AJOXV AKRLJ AMFUW ASPBG AVWKF AZFZN FEDTE FGOYB G-2 HDW HMG HMK HVGLF HZ~ R2- RIG SAE SEW SIN SNS WUQ XJT ZGI AGCQF 9DU AAYXX AGQPQ AIGII CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| ID | FETCH-LOGICAL-c478t-1ae0eba210c1d90743d026603df15a293e21b58749d0891f0b7b0a0a22b6f1b43 |
| ISICitedReferencesCount | 1 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000402218200009&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0165-5728 1872-8421 |
| IngestDate | Thu Oct 02 10:58:48 EDT 2025 Wed Feb 19 02:35:39 EST 2025 Tue Nov 18 19:48:07 EST 2025 Sat Nov 29 07:26:37 EST 2025 Thu Sep 18 02:46:30 EDT 2025 Tue Feb 25 19:59:02 EST 2025 Tue Oct 14 19:36:15 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Language | English |
| License | Copyright © 2017. Published by Elsevier B.V. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c478t-1ae0eba210c1d90743d026603df15a293e21b58749d0891f0b7b0a0a22b6f1b43 |
| Notes | ObjectType-Case Study-2 SourceType-Scholarly Journals-1 ObjectType-Feature-4 content type line 23 ObjectType-Report-1 ObjectType-Article-3 |
| PMID | 28495137 |
| PQID | 1899113027 |
| PQPubID | 23479 |
| PageCount | 5 |
| ParticipantIDs | proquest_miscellaneous_1899113027 pubmed_primary_28495137 crossref_primary_10_1016_j_jneuroim_2017_03_017 crossref_citationtrail_10_1016_j_jneuroim_2017_03_017 elsevier_sciencedirect_doi_10_1016_j_jneuroim_2017_03_017 elsevier_clinicalkeyesjournals_1_s2_0_S0165572816303010 elsevier_clinicalkey_doi_10_1016_j_jneuroim_2017_03_017 |
| PublicationCentury | 2000 |
| PublicationDate | 2017-06-15 |
| PublicationDateYYYYMMDD | 2017-06-15 |
| PublicationDate_xml | – month: 06 year: 2017 text: 2017-06-15 day: 15 |
| PublicationDecade | 2010 |
| PublicationPlace | Netherlands |
| PublicationPlace_xml | – name: Netherlands |
| PublicationTitle | Journal of neuroimmunology |
| PublicationTitleAlternate | J Neuroimmunol |
| PublicationYear | 2017 |
| Publisher | Elsevier B.V |
| Publisher_xml | – name: Elsevier B.V |
| References | Swanton, Fernando, Miller (bb0095) 2014; vol. 122 Ebers (bb0020) 2005; 252 Weinshenker, Bass, Rice, Noseworthy, Carriere, Baskerville (bb0100) 1989; 112 Confavreux, Vukusic, Adeleine (bb0015) 2003; 126 Brex, Ciccarelli, O'Riordan, Sailer, Thompson, Miller (bb0005) 2002; 346 McFarland, Martin (bb0045) 2007; 8 Eriksson, Andersen, Runmarker (bb0025) 2003; 9 Gholipour, Healy, Baruch, Weiner, Chitnis (bb0030) 2011; 76 Runmarker, Andersen (bb0070) 1993; 116 Silver, Good, Barker, MacManus, Thompson, Moseley (bb0090) 1997; 120 Lucchinetti, Gavrilova, Metz, Parisi, Scheithauer, Weigand (bb0115) 2008; 131 Confavreux, Aimard, Devic (bb0010) 1980; 103 Keegan, Pineda, McClelland, Darby, Rodriguez, Weinshenker (bb0035) 2002; 58 Rush, Maclean, Freedman (bb0075) 2015; 11 Scolding, Barnes, Cader, Chataway, Chaudhuri, Coles (bb0080) 2015; 0 Weinshenker, Rice, Noseworthy, Carriere, Baskerville, Ebers (bb0105) 1991; 114 Miller, Soon, Fernando, MacManus, Barker, Yousry (bb0050) 2007; 68 Polman, O'Connor, Havrdova, Hutchinson, Kappos, Miller (bb0065) 2006; 354 Lublin, Reingold (bb0040) 1996; 46 Mowry, Pesic, Grimes, Deen, Bacchetti, Waubant (bb0055) 2009; 72 Polman, Reingold, Edan, Filippi, Hartung, Kappos (bb0060) 2005; 58 Sharief, Thompsen (bb0085) 1991; 29 Weinshenker, O'Brien, Petterson, Noseworthy, Lucchinetti, Dodick (bb0110) 1999; 46 Swanton (10.1016/j.jneuroim.2017.03.017_bb0095) 2014; vol. 122 Keegan (10.1016/j.jneuroim.2017.03.017_bb0035) 2002; 58 Weinshenker (10.1016/j.jneuroim.2017.03.017_bb0100) 1989; 112 Rush (10.1016/j.jneuroim.2017.03.017_bb0075) 2015; 11 Lublin (10.1016/j.jneuroim.2017.03.017_bb0040) 1996; 46 McFarland (10.1016/j.jneuroim.2017.03.017_bb0045) 2007; 8 Weinshenker (10.1016/j.jneuroim.2017.03.017_bb0105) 1991; 114 Confavreux (10.1016/j.jneuroim.2017.03.017_bb0015) 2003; 126 Lucchinetti (10.1016/j.jneuroim.2017.03.017_bb0115) 2008; 131 Polman (10.1016/j.jneuroim.2017.03.017_bb0065) 2006; 354 Sharief (10.1016/j.jneuroim.2017.03.017_bb0085) 1991; 29 Brex (10.1016/j.jneuroim.2017.03.017_bb0005) 2002; 346 Confavreux (10.1016/j.jneuroim.2017.03.017_bb0010) 1980; 103 Polman (10.1016/j.jneuroim.2017.03.017_bb0060) 2005; 58 Eriksson (10.1016/j.jneuroim.2017.03.017_bb0025) 2003; 9 Weinshenker (10.1016/j.jneuroim.2017.03.017_bb0110) 1999; 46 Silver (10.1016/j.jneuroim.2017.03.017_bb0090) 1997; 120 Mowry (10.1016/j.jneuroim.2017.03.017_bb0055) 2009; 72 Ebers (10.1016/j.jneuroim.2017.03.017_bb0020) 2005; 252 Miller (10.1016/j.jneuroim.2017.03.017_bb0050) 2007; 68 Gholipour (10.1016/j.jneuroim.2017.03.017_bb0030) 2011; 76 Scolding (10.1016/j.jneuroim.2017.03.017_bb0080) 2015; 0 Runmarker (10.1016/j.jneuroim.2017.03.017_bb0070) 1993; 116 |
| References_xml | – volume: 29 start-page: 147 year: 1991 end-page: 151 ident: bb0085 article-title: The predictive value of intrathecal immunoglobulin synthesis and magnetic resonance imaging in acute isolated syndromes for subsequent development of multiple sclerosis publication-title: Ann. Neurol. – volume: 68 start-page: 1390 year: 2007 end-page: 1401 ident: bb0050 article-title: MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS publication-title: Neurology – volume: 114 start-page: 1045 year: 1991 end-page: 1056 ident: bb0105 article-title: The natural history of multiple sclerosis: a geographically based study. 3. Multivariate analysis of predictive factors and models of outcome publication-title: Brain – volume: 9 start-page: 260 year: 2003 end-page: 274 ident: bb0025 article-title: Longterm follow up of patients with clinically isolated syndromes, relapsing-remitting and secondary progressive multiple sclerosis publication-title: Mult. Scler. – volume: 11 start-page: 379 year: 2015 end-page: 389 ident: bb0075 article-title: Aggressive multiple sclerosis: proposed definition and treatment algorithm publication-title: Nat. Rev. Neurol. – volume: 0 start-page: 1 year: 2015 end-page: 7 ident: bb0080 article-title: Association of British Neurologists: guidelines for prescribing disease-modifying treatments in multiple sclerosis publication-title: Pract. Neurol. – volume: vol. 122 start-page: 371 year: 2014 end-page: 391 ident: bb0095 article-title: Early prognosis in multiple sclerosis publication-title: Handbook of Clinical Neurology: Multiple Sclerosis – volume: 131 start-page: 1759 year: 2008 end-page: 1775 ident: bb0115 article-title: Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis publication-title: Brain – volume: 58 start-page: 840 year: 2005 end-page: 846 ident: bb0060 article-title: Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria” publication-title: Ann. Neurol. – volume: 116 start-page: 117 year: 1993 end-page: 134 ident: bb0070 article-title: Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up publication-title: Brain – volume: 76 start-page: 1996 year: 2011 end-page: 2001 ident: bb0030 article-title: Demographic and clinical characteristics of malignant multiple sclerosis publication-title: Neurology – volume: 8 start-page: 913 year: 2007 end-page: 919 ident: bb0045 article-title: Multiple sclerosis: a complicated picture of autoimmunity publication-title: Nat. Immunol. – volume: 346 start-page: 158 year: 2002 end-page: 164 ident: bb0005 article-title: A longitudinal study of abnormalities on MRI and disability from multiple sclerosis publication-title: N. Engl. J. Med. – volume: 252 start-page: III/15 year: 2005 end-page: III/20 ident: bb0020 article-title: Prognostic factors for multiple sclerosis: the importance of natural history studies publication-title: J. Neurol. – volume: 103 start-page: 281 year: 1980 end-page: 300 ident: bb0010 article-title: Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients publication-title: Brain – volume: 72 start-page: 602 year: 2009 end-page: 608 ident: bb0055 article-title: Demyelinating events in early multiple sclerosis have inherent severity and recovery publication-title: Neurology – volume: 354 start-page: 899 year: 2006 end-page: 910 ident: bb0065 article-title: A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis publication-title: N. Engl. J. Med. – volume: 58 start-page: 143 year: 2002 end-page: 146 ident: bb0035 article-title: Plasma exchange for severe attacks of CNS demyelination: predictors of response publication-title: Neurology – volume: 112 start-page: 1419 year: 1989 end-page: 1428 ident: bb0100 article-title: The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course publication-title: Brain – volume: 126 start-page: 770 year: 2003 end-page: 782 ident: bb0015 article-title: Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process publication-title: Brain – volume: 46 start-page: 907 year: 1996 end-page: 911 ident: bb0040 article-title: Defining the clinical course of multiple sclerosis: results of an international survey publication-title: Neurology – volume: 46 start-page: 878 year: 1999 end-page: 886 ident: bb0110 article-title: A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease publication-title: Ann. Neurol. – volume: 120 start-page: 1149 year: 1997 end-page: 1161 ident: bb0090 article-title: Sensitivity of contrast enhanced MRI in multiple sclerosis. Effects of gadolinium dose, magnetization transfer contrast and delayed imaging publication-title: Brain – volume: 9 start-page: 260 year: 2003 ident: 10.1016/j.jneuroim.2017.03.017_bb0025 article-title: Longterm follow up of patients with clinically isolated syndromes, relapsing-remitting and secondary progressive multiple sclerosis publication-title: Mult. Scler. doi: 10.1191/1352458503ms914oa – volume: vol. 122 start-page: 371 year: 2014 ident: 10.1016/j.jneuroim.2017.03.017_bb0095 article-title: Early prognosis in multiple sclerosis doi: 10.1016/B978-0-444-52001-2.00015-7 – volume: 58 start-page: 143 year: 2002 ident: 10.1016/j.jneuroim.2017.03.017_bb0035 article-title: Plasma exchange for severe attacks of CNS demyelination: predictors of response publication-title: Neurology doi: 10.1212/WNL.58.1.143 – volume: 72 start-page: 602 year: 2009 ident: 10.1016/j.jneuroim.2017.03.017_bb0055 article-title: Demyelinating events in early multiple sclerosis have inherent severity and recovery publication-title: Neurology doi: 10.1212/01.wnl.0000342458.39625.91 – volume: 46 start-page: 878 year: 1999 ident: 10.1016/j.jneuroim.2017.03.017_bb0110 article-title: A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease publication-title: Ann. Neurol. doi: 10.1002/1531-8249(199912)46:6<878::AID-ANA10>3.0.CO;2-Q – volume: 68 start-page: 1390 year: 2007 ident: 10.1016/j.jneuroim.2017.03.017_bb0050 article-title: MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS publication-title: Neurology doi: 10.1212/01.wnl.0000260064.77700.fd – volume: 0 start-page: 1 year: 2015 ident: 10.1016/j.jneuroim.2017.03.017_bb0080 article-title: Association of British Neurologists: guidelines for prescribing disease-modifying treatments in multiple sclerosis publication-title: Pract. Neurol. – volume: 116 start-page: 117 year: 1993 ident: 10.1016/j.jneuroim.2017.03.017_bb0070 article-title: Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up publication-title: Brain doi: 10.1093/brain/116.1.117 – volume: 112 start-page: 1419 year: 1989 ident: 10.1016/j.jneuroim.2017.03.017_bb0100 article-title: The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course publication-title: Brain doi: 10.1093/brain/112.6.1419 – volume: 29 start-page: 147 year: 1991 ident: 10.1016/j.jneuroim.2017.03.017_bb0085 article-title: The predictive value of intrathecal immunoglobulin synthesis and magnetic resonance imaging in acute isolated syndromes for subsequent development of multiple sclerosis publication-title: Ann. Neurol. doi: 10.1002/ana.410290206 – volume: 120 start-page: 1149 year: 1997 ident: 10.1016/j.jneuroim.2017.03.017_bb0090 article-title: Sensitivity of contrast enhanced MRI in multiple sclerosis. Effects of gadolinium dose, magnetization transfer contrast and delayed imaging publication-title: Brain doi: 10.1093/brain/120.7.1149 – volume: 131 start-page: 1759 year: 2008 ident: 10.1016/j.jneuroim.2017.03.017_bb0115 article-title: Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis publication-title: Brain doi: 10.1093/brain/awn098 – volume: 126 start-page: 770 year: 2003 ident: 10.1016/j.jneuroim.2017.03.017_bb0015 article-title: Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process publication-title: Brain doi: 10.1093/brain/awg081 – volume: 354 start-page: 899 year: 2006 ident: 10.1016/j.jneuroim.2017.03.017_bb0065 article-title: A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa044397 – volume: 114 start-page: 1045 year: 1991 ident: 10.1016/j.jneuroim.2017.03.017_bb0105 article-title: The natural history of multiple sclerosis: a geographically based study. 3. Multivariate analysis of predictive factors and models of outcome publication-title: Brain doi: 10.1093/brain/114.2.1045 – volume: 58 start-page: 840 year: 2005 ident: 10.1016/j.jneuroim.2017.03.017_bb0060 article-title: Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria” publication-title: Ann. Neurol. doi: 10.1002/ana.20703 – volume: 8 start-page: 913 year: 2007 ident: 10.1016/j.jneuroim.2017.03.017_bb0045 article-title: Multiple sclerosis: a complicated picture of autoimmunity publication-title: Nat. Immunol. doi: 10.1038/ni1507 – volume: 103 start-page: 281 year: 1980 ident: 10.1016/j.jneuroim.2017.03.017_bb0010 article-title: Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients publication-title: Brain doi: 10.1093/brain/103.2.281 – volume: 76 start-page: 1996 year: 2011 ident: 10.1016/j.jneuroim.2017.03.017_bb0030 article-title: Demographic and clinical characteristics of malignant multiple sclerosis publication-title: Neurology doi: 10.1212/WNL.0b013e31821e559d – volume: 252 start-page: III/15 issue: Suppl. 3 year: 2005 ident: 10.1016/j.jneuroim.2017.03.017_bb0020 article-title: Prognostic factors for multiple sclerosis: the importance of natural history studies publication-title: J. Neurol. – volume: 346 start-page: 158 year: 2002 ident: 10.1016/j.jneuroim.2017.03.017_bb0005 article-title: A longitudinal study of abnormalities on MRI and disability from multiple sclerosis publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa011341 – volume: 11 start-page: 379 year: 2015 ident: 10.1016/j.jneuroim.2017.03.017_bb0075 article-title: Aggressive multiple sclerosis: proposed definition and treatment algorithm publication-title: Nat. Rev. Neurol. doi: 10.1038/nrneurol.2015.85 – volume: 46 start-page: 907 year: 1996 ident: 10.1016/j.jneuroim.2017.03.017_bb0040 article-title: Defining the clinical course of multiple sclerosis: results of an international survey publication-title: Neurology doi: 10.1212/WNL.46.4.907 |
| SSID | ssj0015349 |
| Score | 2.2032325 |
| Snippet | Objective
The aim of this case report is to highlight some important features of rapidly evolving Multiple Sclerosis.
In a small proportion of patients,... Abstract Objective The aim of this case report is to highlight some important features of rapidly evolving Multiple Sclerosis. Background In a small proportion... Objective The aim of this case report is to highlight some important features of rapidly evolving Multiple Sclerosis. In a small proportion of patients,... Objective The aim of this case report is to highlight some important features of rapidly evolving Multiple Sclerosis.Objective The aim of this case report is... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 42 |
| SubjectTerms | Adult Allergy and Immunology Brain - diagnostic imaging Disability Evaluation Humans Image Processing, Computer-Assisted Immunoglobulins, Intravenous - therapeutic use Immunologic Factors - therapeutic use Magnetic Resonance Imaging Male Multiple Sclerosis - diagnostic imaging Multiple Sclerosis - pathology Multiple Sclerosis - physiopathology Multiple Sclerosis - therapy Neurology |
| Title | Early predictors of rapidly evolving multiple sclerosis: A case report |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0165572816303010 https://www.clinicalkey.es/playcontent/1-s2.0-S0165572816303010 https://dx.doi.org/10.1016/j.jneuroim.2017.03.017 https://www.ncbi.nlm.nih.gov/pubmed/28495137 https://www.proquest.com/docview/1899113027 |
| Volume | 307 |
| WOSCitedRecordID | wos000402218200009&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals 2021 customDbUrl: eissn: 1872-8421 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0015349 issn: 0165-5728 databaseCode: AIEXJ dateStart: 19950101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3rb9MwED-xDiG-INh4lMdkJMQXlGLnZYdvFdoESJuQKFK_WU7iaKkgqZoObf8950eyQakYIL6klSX3Ut_P57vzPQBeoIoQ6pDyIKvQRIkRwoEoytJEAiiexyiVw9w2m-AnJ2I-zz76HpudbSfAm0acn2fL_8pqHENmm9TZP2D38KM4gN-R6fhEtuPzWox3JYuXK3MDY1vpoDq4Usu6xFGNwsh6EIY4wg5n40FZdy5FvcBDzd8jbFFbbQHM2mSV_OCQ9_7o1gmOi-5UNfWr2eR4MoToKJ_6cDVQ37sbmI2NcwmXzge2kQfj3JJpEiTcp3l7uRq5drZeMroaWv6MdV7HDentHAmLycL_FRN5x20NWpff-VNl7E-GrKGKOqWx7OgO7IY8ycQIdqfvD-cfhuukJHJ2UP-aV1LFf01tm5ayzQqx2sjsLtzx_CBTx_57cEM3e7A_bdS6_XpBXhIb2GsZtAe3jn38xD4cWXCQS3CQtiIeHKQHB-nBQQZwvCFTYqBBHDTuw-ejw9nbd4HvpBEUMRfrgClNda7QvC9YadwhUYm2d0qjsmKJQo1PhyxPBI-zkoqMVTTnOVVUhWGeViyPowcwatpGPwISm3ZNaaIZ4zoOi0opoUOeJiUtWRWJfAxJv3Ky8GXmTbeTL7KPJ1zIfsWlWXFJI4kfY3g9zFu6Qiu_ncF7xsg-jRgPPolo-ruZuvPbuJNMdqGkcgNhY8iGmV5Fdarntag-79EjUYabiznV6PYMqQm00mwEwRgeOlgNa4DqIxpBEX_8D5SfwO3LrfwURuvVmX4GN4tv67pbHcAOn4sDv2W-A9FEzr0 |
| linkProvider | Elsevier |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Early+predictors+of+rapidly+evolving+multiple+sclerosis%3A+A+case+report&rft.jtitle=Journal+of+neuroimmunology&rft.au=Fernando%2C+Kryshani+T.M.&rft.au=James%2C+Michael&rft.date=2017-06-15&rft.pub=Elsevier+B.V&rft.issn=0165-5728&rft.volume=307&rft.spage=42&rft.epage=46&rft_id=info:doi/10.1016%2Fj.jneuroim.2017.03.017&rft.externalDocID=S0165572816303010 |
| thumbnail_m | http://cvtisr.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F01655728%2FS0165572817X00064%2Fcov150h.gif |